178 results
6-K
EX-99.2
REPCF
Replicel Life Sciences Inc.
30 Nov 23
Condensed Consolidated Interim Financial Statements
1:05pm
or corticosteroids which are limited in efficacy. Another advantage of RCT-01 is the autologous nature of the cellular product, thereby reducing the likelihood … in a form prepared by the Securities and Exchange Commission, which provides information about penny stocks and the nature and level of risks
6-K
EX-99.2
REPCF
Replicel Life Sciences Inc.
24 Oct 23
Condensed Consolidated Interim Financial Statements
11:10am
are limited in efficacy. Another advantage of RCT-01 is the autologous nature of the cellular product, thereby reducing the likelihood of adverse … risk disclosure document in a form prepared by the Securities and Exchange Commission, which provides information about penny stocks and the nature
6-K
EX-99.2
REPCF
Replicel Life Sciences Inc.
30 Aug 23
Notice of Annual General and Special Meeting of Shareholders
5:15pm
nature";
B. amendments for the purpose of curing any ambiguity, error or omission in the Equity Incentive Plan or to correct or supplement any provision … and the Board may make any changes which may include but are not limited to:
(i) amendments of a "housekeeping nature"; and
(ii) amendments for the purpose
6-K
EX-99.2
REPCF
Replicel Life Sciences Inc.
30 May 23
Condensed Consolidated Interim Financial Statements
5:40pm
is the autologous nature of the cellular product, thereby reducing the likelihood of adverse immune reactions upon administration.
Pilot Clinical Trials
Phase … stocks and the nature and level of risks in the penny stock market. The broker-dealer also must provide the customer with current bid and offer
6-K
EX-99.2
REPCF
Replicel Life Sciences Inc.
18 May 23
RepliCel Applies to Extend Warrant and Stock Option Expiry Dates and Announces Grant of Stock Options
1:58pm
nature and material terms of any agreement entered into by the issuer, or a related party of the issuer, with an interested party or a joint actor
6-K
EX-99.2
94jw8luxa20mirkqd
29 Nov 22
Condensed Consolidated Interim Financial Statements
6:44pm
20-F/A
ofu83gzr
12 Sep 22
Annual report (foreign) (amended)
6:17pm
6-K
EX-99.2
9ol9n ms4
6 Sep 22
Condensed Consolidated Interim Financial Statements
12:42pm
6-K
EX-99.1
v3h9yvl hg
4 Aug 22
Current report (foreign)
11:41am
6-K
EX-99.4
jte2 9llac26eq6m04
7 Jul 22
RepliCel Provides Update on Private Placement
3:36pm
6-K
EX-99.5
6ke5rh
10 May 22
Replicel Life Sciences Inc. Announces Application for a Management Cease Trade Order
4:34pm
D
datjm2r3 s9h
10 May 22
$592.73K in equity / options / securities to be acquired, sold $592.73K, 2 investors
3:57pm
D
2ez52oc4opzp
20 Dec 21
$777.66K in equity, sold $777.66K, 1 investor
12:00am
6-K
EX-99.2
y3l6jw8yml0
30 Nov 21
Condensed Consolidated Interim Financial Statements
1:50pm
6-K
EX-99.1
u8ygliy 11
12 Oct 21
RepliCel and University of Victoria Collaboration Leads to Bioengineering Innovations, Funding, and Patents
1:06pm
6-K
EX-99.2
v22jxlv7
31 Aug 21
Condensed Consolidated Interim Financial Statements
1:45pm
6-K
EX-99.2
bu04qhg0bdsu0i b8t1
18 Aug 21
RepliCel Life Sciences Announces Closing of Debt Settlement
12:34pm
6-K
EX-99.8
3u18sxd1r8b9yd fwg1
18 Aug 21
Current report (foreign)
12:20pm